Noticias

The Wall Street Journal7h agobearish

Regeneron Melanoma Drug Trial Disappoints and Shares Slide

Shares tumbled after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.

The Wall Street Journal6d agoneutral

Health Care Roundup: Market Talk

Find insight on the deal between Hengrui Pharmaceuticals and Bristol Myers Squibb and more in the latest Market Talks covering the health care sector.

The Wall Street Journal6d agoneutral

Bristol-Myers Squibb and China’s Hengrui Pharma Forge Tie-Up

U.S. pharma giant Bristol-Myers Squibb has struck a partnership and licensing deal with Chinese drugmaker Hengrui, in a deal that could worth more than $15 billion.

BMY

MarketBeat9d agoneutral

Xenon Pharmaceuticals Q1 Earnings Call Highlights

Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure medicine, after reporting positive Phase 3 data in focal onset seizures during the first q

BMY